```html

Noninfectious Uveitis – A Comprehensive Patient Guide

Overview

Uveitis is inflammation of the uvea, the middle layer of the eye that includes the iris, ciliary body, and choroid. When the inflammation is not caused by bacteria, viruses, fungi, or parasites, it is termed **noninfectious uveitis**. This form accounts for roughly 70–90 % of all uveitis cases in the United States and Europe, affecting an estimated 0.1–0.5 % of the population (about 1–3 million people).

Noninfectious uveitis can develop at any age but shows two peaks: 1) children and adolescents (often associated with juvenile idiopathic arthritis) and 2) adults aged 30–50 years (commonly linked to systemic autoimmune diseases such as sarcoidosis or ankylosing spondylitis). It affects both sexes, though some underlying conditions (e.g., Behçet’s disease) are more common in males.

Symptoms

Symptoms may be sudden or develop gradually and often differ according to which part of the uvea is inflamed (anterior, intermediate, posterior, or pan‑uveitis). Common features include:

• Eye redness – usually sectoral (around the iris) in anterior uveitis.
• Pain – deep, aching pain that worsens with light exposure (photophobia).
• Blurred or decreased vision – may be mild or severe depending on location of inflammation.
• Floaters – tiny specks or cobweb‑like shadows that drift across the visual field, typical of intermediate or posterior uveitis.
• Photophobia – heightened sensitivity to bright light.
• Decreased night vision – especially with posterior segment involvement.
• Eye tearing – reflex tearing due to irritation.
• Conjunctival injection – visible blood vessels on the white of the eye.
• Redness of the eyelid margins – may mimic blepharitis.
• Headache or facial pain – especially when inflammation spreads to adjacent structures.

Causes and Risk Factors

Underlying systemic diseases

Noninfectious uveitis is usually a manifestation of an autoimmune or autoinflammatory disorder. The most common associated conditions are:

• HLA‑B27–related seronegative spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis).
• Juvenile idiopathic arthritis (JIA) – the leading cause of chronic uveitis in children.
• Sarcoidosis – granulomatous disease that frequently involves the posterior segment.
• Behçet’s disease – causes recurrent, often severe, posterior uveitis.
• Inflammatory bowel disease (Crohn’s, ulcerative colitis).
• Multiple sclerosis – may trigger intermediate uveitis.
• Systemic lupus erythematosus, rheumatoid arthritis, and other connective‑tissue diseases.

Idiopathic (unknown) cases

In 30–40 % of patients, no systemic disease is identified despite thorough work‑up; the cause remains “idiopathic.”

Risk factors

• Age < 40 years (particularly for HLA‑B27‑related uveitis).
• Family history of autoimmune disease.
• Existing systemic inflammatory disease.
• Female sex in childhood uveitis (JIA‑related).
• Smoking – linked to increased severity of uveitis in Behçet’s disease.

Diagnosis

Diagnosis requires both a detailed clinical assessment and targeted investigations.

Clinical examination

• Slit‑lamp biomicroscopy – visualizes the anterior chamber, iris, and lens; detects cells/flare indicating inflammation.
• Fundoscopy (indirect ophthalmoscopy) – assesses the vitreous, retina, and choroid for lesions, vasculitis, or macular edema.
• Intra‑ocular pressure (IOP) measurement – inflammation or steroid treatment can raise or lower IOP.

Ancillary tests

• Optical coherence tomography (OCT) – cross‑sectional imaging of the retina; detects macular edema.
• Fluorescein angiography (FA) – highlights retinal vasculitis and leakage.
• Indocyanine green angiography (ICGA) – useful for choroidal involvement.
• Ultrasound B‑scan – assesses posterior segment when view is blocked.

Laboratory work‑up

Tests are directed by suspected systemic disease:

• Complete blood count, ESR, CRP – markers of inflammation.
• HLA‑B27 typing.
• Serologic panels for syphilis, tuberculosis, Lyme disease (to rule out infection).
• Ana, ENA panel, rheumatoid factor – screen for connective‑tissue disease.
• Serum ACE and calcium – evaluate for sarcoidosis.
• Chest X‑ray or CT – look for hilar lymphadenopathy in sarcoidosis.
• Joint imaging or gastroenterology referral when underlying disease is suspected.

Treatment Options

Treatment aims to control inflammation promptly, preserve vision, and treat any underlying systemic disease. Therapy is usually tiered from topical agents to systemic immunosuppression.

Medications

• Topical corticosteroids (prednisolone acetate 1 %) – first line for mild anterior uveitis. Note: long‑term use raises risk of cataract and glaucoma.
• Cycloplegic agents (atropine, cyclopentolate) – relieve pain from ciliary spasm and prevent synechiae.
• Periocular injections (triamcinolone acetonide) – deliver higher steroid concentrations to posterior segment.
• Systemic corticosteroids (oral prednisone 0.5–1 mg/kg) – for intermediate, posterior, or bilateral disease.
• Steroid‑sparing immunomodulatory therapy (IMT) – recommended when steroids are needed >3 months or when side‑effects emerge:
  • Antimetabolites: methotrexate, mycophenolate mofetil, azathioprine.
  • Calcineurin inhibitors: cyclosporine, tacrolimus.
  • Biologic agents: anti‑TNFα (adalimumab, infliximab), anti‑IL‑6 (tocilizumab), interferon‑α.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – oral or topical NSAIDs can help with mild pain, but do not control inflammation.

Procedures

• Pars plana vitrectomy – removes inflammatory media and vitreous opacities, useful in chronic or recalcitrant posterior uveitis.
• Laser photocoagulation – treats retinal neovascularization or focal leakage.
• Implantable corticosteroid devices (e.g., fluocinolone acetonide or dexamethasone intravitreal implants) – provide long‑acting steroid release for chronic posterior disease.

Lifestyle and supportive measures

• Wear UV‑protective sunglasses to reduce photophobia.
• Maintain regular follow‑up appointments (often every 1–3 months initially).
• Report any new visual changes promptly.
• Adopt a low‑salt diet and avoid smoking, which can exacerbate systemic inflammation.

Living with Noninfectious Uveitis

Daily management tips

• Medication adherence – set alarms or use a pill‑box; never stop steroids abruptly.
• Eye‑drop technique – wash hands, tilt head back, pull lower eyelid down, avoid touching tip to eye, close eyelid gently for 2 minutes to enhance absorption.
• Monitor vision – keep a simple log of visual acuity (e.g., using a printable Snellen chart). Sudden decline warrants urgent review.
• Protect the eyes – use protective eyewear during sports or construction work.
• Manage systemic disease – collaborate with rheumatologists, gastroenterologists, or neurologists as needed.
• Stress reduction – chronic inflammation can be worsened by stress; practice relaxation techniques (mindfulness, yoga).
• Regular eye‑health checks – even when asymptomatic, annual dilated examinations are recommended.

Emotional wellbeing

Living with a chronic eye condition can be anxiety‑provoking. Seek counseling, join patient support groups (e.g., Uveitis Foundation), and stay informed about new therapies.

Prevention

Because many cases are linked to systemic autoimmune disease, primary prevention focuses on early detection and control of those conditions.

• Screen patients with known HLA‑B27‑associated arthritis for ocular symptoms at baseline and annually.
• Maintain optimal control of systemic disease with disease‑modifying agents.
• Avoid exposure to known ocular irritants (smoke, chemicals) that could trigger flare‑ups.
• Vaccinations (influenza, pneumococcal) are recommended for patients on immunosuppressants to reduce infection‑related complications.

Complications

If inflammation is not adequately controlled, several sight‑threatening complications may develop:

• Cataract formation – especially posterior subcapsular cataracts from long‑term steroids.
• Glaucoma – steroid‑induced or secondary to trabecular meshwork damage.
• Macular edema – accumulation of fluid in the central retina, leading to central vision loss.
• Retinal neovascularization – can cause vitreous hemorrhage.
• Epiretinal membrane or tractional retinal detachment – from chronic inflammation and scar tissue.
• Optic neuropathy – irreversible vision loss if optic nerve is damaged.
• Band keratopathy – calcium deposition in the cornea causing visual haze.

According to a 2021 systematic review in *Ocular Immunology & Inflammation*, up to 35 % of patients with chronic noninfectious uveitis develop at least one sight‑threatening complication within 10 years.

When to Seek Emergency Care

References

• American Academy of Ophthalmology. Uveitis Preferred Practice Pattern. 2023.
• Mayo Clinic. “Uveitis.” Updated 2022. https://www.mayoclinic.org
• Cleveland Clinic. “Non‑infectious Uveitis.” 2024. https://my.clevelandclinic.org
• National Eye Institute. “Uveitis.” 2022. https://nei.nih.gov
• World Health Organization. “Blindness and Vision Impairment.” 2021.
• Jabs DA, et al. “Standardization of Uveitis Nomenclature.” *Ocular Immunology & Inflammation*. 2021.
• Lee SY, et al. “Long‑term Outcomes of Noninfectious Uveitis Treated with Biologics.” *Ophthalmology*. 2022.

```